Talia Golan
Tel Aviv University
30 Papers
26 Citations
Talia Golan is an academic researcher from Tel Aviv University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 15, co-authored 30 publications. Previous affiliations of Talia Golan include Sheba Medical Center.
Chat about Author
Papers
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan,Pascal Hammel,Michele Reni,Eric Van Cutsem,Teresa Macarulla,Michael J. Hall,Joon Oh Park,Daniel Hochhauser,Dirk Arnold,Do Youn Oh,Anke Reinacher-Schick,Giampaolo Tortora,Giampaolo Tortora,Hana Algül,Eileen M. O'Reilly,David McGuinness,Karen Y. Cui,Katia Schlienger,Gershon Y. Locker,Hedy L. Kindler +19 more
TL;DR: Among patients with a germline BRCA mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo, and there was no significant between-group difference in health-related quality of life.
1.9K
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs,Toshihiko Doi,Raymond Jang,Raymond Jang,Kei Muro,Taroh Satoh,Manuela Machado,Weijing Sun,Weijing Sun,Shadia I. Jalal,Manish A. Shah,Jean Phillipe Metges,Marcelo Garrido,Talia Golan,Talia Golan,Mario Mandalà,Zev A. Wainberg,Daniel V.T. Catenacci,Atsushi Ohtsu,Kohei Shitara,Ravit Geva,Jonathan Bleeker,Andrew H. Ko,Geoffrey Y. Ku,Philip A. Philip,Peter C. Enzinger,Yung-Jue Bang,Diane Levitan,Jiangdian Wang,Minori Koshiji Rosales,Rita P. Dalal,Harry H. Yoon +31 more
TL;DR: Pembrolizumab monotherapy demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment.
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Deborah Nejman,Ilana Livyatan,Garold Fuks,Nancy Gavert,Yaara Zwang,Leore T. Geller,Aviva Rotter-Maskowitz,Roi Weiser,Roi Weiser,Giuseppe Mallel,Elinor Gigi,Arnon Meltser,Gavin M. Douglas,Iris Kamer,Vancheswaran Gopalakrishnan,Tali Dadosh,Smadar Levin-Zaidman,Sofia Avnet,Tehila Atlan,Zachary A. Cooper,Reetakshi Arora,Alexandria P. Cogdill,Abdul Wadud Khan,Gabriel Ologun,Yuval Bussi,Adina Weinberger,Maya Lotan-Pompan,Ofra Golani,Gili Perry,Merav Rokah,Keren Bahar-Shany,Elisa A. Rozeman,Christian U. Blank,Anat Ronai,Ron Shaoul,Amnon Amit,Amnon Amit,Tatiana Dorfman,Ran Kremer,Zvi R. Cohen,Zvi R. Cohen,Sagi Harnof,Sagi Harnof,Tali Siegal,Einav Yehuda-Shnaidman,Einav Nili Gal-Yam,Hagit Shapira,Nicola Baldini,Morgan G. I. Langille,Alon Ben-Nun,Alon Ben-Nun,Bella Kaufman,Bella Kaufman,Aviram Nissan,Talia Golan,Talia Golan,Maya Dadiani,Keren Levanon,Keren Levanon,Jair Bar,Jair Bar,Shlomit Yust-Katz,Shlomit Yust-Katz,Iris Barshack,Iris Barshack,Daniel S. Peeper,Dan J. Raz,Eran Segal,Jennifer A. Wargo,Judith Sandbank,Noam Shental,Ravid Straussman +71 more
TL;DR: A comprehensive analysis of the tumor microbiome was undertaken, studying 1526 tumors and their adjacent normal tissues across seven cancer types, finding that each tumor type has a distinct microbiome composition and that breast cancer has a particularly rich and diverse microbiome.
1.6K
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.
Leore T. Geller,Michal Barzily-Rokni,Tal Danino,Oliver Jonas,Oliver Jonas,Noam Shental,Deborah Nejman,Nancy Gavert,Yaara Zwang,Zachary A. Cooper,Kevin Shee,Christoph A. Thaiss,Alexandre Reuben,Jonathan Livny,Roi Avraham,Dennie T. Frederick,Matteo Ligorio,Kelly Chatman,Stephen Johnston,Carrie M. Mosher,Alexander Brandis,Garold Fuks,Candice Gurbatri,Vancheswaran Gopalakrishnan,Michael P. Kim,Mark W. Hurd,Matthew H.G. Katz,Jason B. Fleming,Anirban Maitra,David Smith,Matthew Skalak,Jeffrey Bu,Monia Michaud,Sunia A. Trauger,Iris Barshack,Iris Barshack,Talia Golan,Talia Golan,Judith Sandbank,Keith T. Flaherty,Anna Mandinova,Anna Mandinova,Wendy S. Garrett,Wendy S. Garrett,Sarah P. Thayer,Cristina R. Ferrone,Curtis Huttenhower,Curtis Huttenhower,Sangeeta N. Bhatia,Dirk Gevers,Jennifer A. Wargo,Todd R. Golub,Todd R. Golub,Ravid Straussman +53 more
TL;DR: By studying colon cancer models, it is found that bacteria can metabolize the chemotherapeutic drug gemcitabine into its inactive form, 2′,2′-difluorodeoxyuridine, seen primarily in Gammaproteobacteria.
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Bruno Bockorny,Bruno Bockorny,Valerya Semenisty,Teresa Macarulla,Erkut Borazanci,Brian M. Wolpin,Salomon M. Stemmer,Salomon M. Stemmer,Talia Golan,Talia Golan,Ravit Geva,Ravit Geva,Mitesh J. Borad,Katrina S. Pedersen,Joon Oh Park,Robert A. Ramirez,David Gutierrez Abad,Jaime Feliu,Andrés Muñoz,Mariano Ponz-Sarvise,Amnon Peled,Tzipora M. Lustig,Osnat Bohana-Kashtan,Stephen M. Shaw,Ella Sorani,Marya F. Chaney,Shaul Kadosh,Abi Vainstein Haras,Daniel D. Von Hoff,Manuel Hidalgo,Manuel Hidalgo +30 more
TL;DR: Results from the phase IIa COMBAT trial combining CXCR4 and PD-1 inhibition in patients with metastatic cancer show encouraging clinical responses in association with enhanced antitumor immune activation.
411